ChiCTR2200058956 版本V1.1 版本创建时间2023/01/10 16:32:57 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200058956 

最近更新日期:

Date of Last Refreshed on:

2023-01-10 16:27:20 

注册时间:

Date of Registration:

2022-04-20 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

术前口服碳水化合物对老年胃肠道手术术后谵妄的影响

Public title:

Randomized clinical trial of the effect of preoperative oral carbohydrate on postoperative delirium among elderly patients undergoing gastrointestinal surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

术前口服碳水化合物对腹腔镜下老年胃肠道根治性手术术后谵妄的影响

Scientific title:

Randomized clinical trial of the effect of preoperative oral carbohydrate on postoperative delirium among elderly patients undergoing laparoscopic radical gastrointestinal surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

文亚玲 

研究负责人:

左友波 

Applicant:

Wen Yaling 

Study leader:

Zuo Youbo 

申请注册联系人电话:

Applicant telephone:

+86 15181948776

研究负责人电话:

Study leader's
telephone:

+86 13808271734

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2691220891@qq.com

研究负责人电子邮件:

Study leader's E-mail:

442687398@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省南充市顺庆区茂源南路1号

研究负责人通讯地址:

四川省南充市顺庆区茂源南路1号

Applicant address:

1 Maoyuan Road South, Shunqing District, Nanchong, Sichuan

Study leader's address:

1 Maoyuan Road South, Shunqing District, Nanchong, Sichuan

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

川北医学院附属医院麻醉科

Applicant's institution:

Department of Anesthesiology, Affiliated Hospital of North Sichuan Medical College

研究负责人所在单位:

川北医学院附属医院麻醉科

Affiliation of the Leader:

Department of Anesthesiology, Affiliated Hospital of North Sichuan Medical College

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2021ER164-1

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

川北医学院附属医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Affiliated Hospital of North Sichuan Medical College

伦理委员会批准日期:

Date of approved by ethic committee:

2021-11-17 00:00:00

伦理委员会联系人:

胡春梅

Contact Name of the ethic committee:

Hu Chunmei

伦理委员会联系地址:

四川省南充市顺庆区茂源南路1号

Contact Address of the ethic committee:

1 Maoyuan Road South, Shunqing District, Nanchong, Sichuan

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 817 2262124

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

川北医学院附属医院麻醉科

Primary sponsor:

Department of Anesthesiology, Affiliated Hospital of North Sichuan Medical College

研究实施负责(组长)单位地址:

四川省南充市顺庆区茂源南路1号

Primary sponsor's address:

1 Maoyuan Road South, Shunqing District, Nanchong, Sichuan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

南充

Country:

China

Province:

Sichuan

City:

Nanchong

单位(医院):

川北医学院附属医院麻醉科

具体地址:

顺庆区茂源南路1号

Institution
hospital:

Affiliated Hospital of North Sichuan Medical College

Address:

1 Maoyuan Road South, Shunqing District

经费或物资来源:

研究生科研经费

Source(s) of funding:

reseach funding for postgraduate

研究疾病:

术后谵妄  

Target disease:

Postoperative delirium

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探讨术前口服碳水化合物对腹腔镜下老年胃肠道根治性手术术后谵妄的影响。  

Objectives of Study:

To explore the effect of preoperative oral carbohydrate on postoperative delirium among elderly patients undergoing laparoscopic radical gastrointestinal surgery.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.择期行腹腔镜下根治性胃肠道手术;2.年龄65~79岁;3.ASA分级Ⅰ~Ⅱ级。

Inclusion criteria

1.Elective laparoscopic radical gastrointestinal surgery;2.Aged 65~79 years;3.ASA grade Ⅰ~Ⅱ.

排除标准:

1.合并糖尿病、糖耐量异常及使用影响胰岛素敏感性的药物;2. 体重在过去6个月下降超过10%;3.患者伴有恶心、呕吐、胃食管反流、胃排空障碍、幽门梗阻等;4.合并严重脑、心、肺、肝、肾脏疾病;5.怀疑或确有酒精、药物滥用史者;6.有阿尔兹海默病、帕金森病、谵妄病史者;7.有严重感觉缺陷(如视力、听力障碍)或其他原因导致的无法与访视者正常交流而影响评价者。

Exclusion criteria:

1.Diabetes mellitus, abnormal glucose tolerance, and use of drugs that affect insulin sensitivity;2.Weight loss of more than 10% in the last 6 months;3.Onditions (including pharmacological treatment) known to affect gastric emptying rate;4.Complicated by severe brain, heart, lung, liver, and kidney disease;5.Suspected or indeed have a history of alcohol or drug abuse; 6. Those with a history of Alzheimer's disease, Parkinson's disease, and delirium;6.A history of Alzheimer's disease, Parkinson's disease, and delirium;7.Severe sensory deficits (e.g., visual impairment, hearing impairment) or other reasons that result in the inability to communicate properly with the visitor affect the reviewer.

研究实施时间:

Study execute time:

From 2021-11-17 00:00:00 To 2022-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-05-01 00:00:00 To 2022-09-30 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

47

Group:

Experimental group

Sample size:

干预措施:

术前2h口服含28g的碳水化合物饮料200ml

干预措施代码:

Intervention:

200ml of carbohydrate drink containing 28g orally 28g before surgery

Intervention code:

组别:

对照组

样本量:

47

Group:

Control group

Sample size:

干预措施:

术前禁食禁饮

干预措施代码:

Intervention:

Preoperative fasting and drinking

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

南充 

Country:

China

Province:

Sichuan

City:

Nanchong

单位(医院):

川北医学院附属医院 

单位级别:

三级甲等 

Institution
hospital:

Affiliated Hospital of Sichuan Medical College

Level of the institution:

Teritary A

测量指标:

Outcomes:

指标中文名:

3分钟谵妄诊断量表

指标类型:

主要指标

Outcome:

3-minute delirium diagnostic scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清胰高血糖素样1

指标类型:

主要指标

Outcome:

serum glucagon-like 1

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

葡萄糖依赖性促胰岛素激素

指标类型:

主要指标

Outcome:

glucose-dependent insulinotropic polypeptide

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肿瘤坏死因子α

指标类型:

次要指标

Outcome:

tumor necrosis factor-α

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白细胞介素-6

指标类型:

次要指标

Outcome:

interleukin-6

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

C反应蛋白

指标类型:

次要指标

Outcome:

C-reactive protein

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视觉模拟评分

指标类型:

次要指标

Outcome:

visual analogue scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

收缩压

指标类型:

次要指标

Outcome:

systolic blood pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

舒张压

指标类型:

次要指标

Outcome:

diastolic blood pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

平均血压

指标类型:

次要指标

Outcome:

mean blood pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率

指标类型:

次要指标

Outcome:

heart rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胃窦部横截面积

指标类型:

附加指标

Outcome:

cross-sectional area

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age 79 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由第三方采用随机数表法产生

Randomization Procedure (please state who generates the random number sequence and by what method):

The random sequence will be generated by the third party using random number table.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成后6个月内公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Within six months after the trial complete

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

未说明

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Not stated

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2022-04-20 21:41:11